Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Sales | 4,855,539 | 4,431,886 | 5,003,337 | 4,798,162 | 4,511,273 |
| Cost of Goods | 809,335 | 704,824 | 795,512 | 804,546 | 756,175 |
| Gross Profit | 4,046,204 | 3,727,062 | 4,207,825 | 3,993,617 | 3,755,098 |
| Operating Expenses | 2,035,683 | 1,684,013 | 1,800,532 | 2,244,938 | 1,830,342 |
| Operating Income | 2,010,856 | 2,043,873 | 2,407,805 | 1,749,224 | 1,924,931 |
| Interest Expense | 43,803 | 76,656 | 191,715 | 119,470 | 123,521 |
| Other Income | 25,434 | 14,326 | 2,512 | 2,972 | 2,533 |
| Pre-tax Income | 1,992,487 | 1,981,543 | 2,218,602 | 1,632,726 | 1,803,943 |
| Income Tax | 375,701 | 412,231 | 461,415 | 347,613 | 285,037 |
| Net Income Continuous | 1,616,786 | 1,569,313 | 1,757,187 | 1,285,113 | 1,518,906 |
| Net Income | $1,616,786 | $1,569,313 | $1,757,187 | $1,285,113 | $1,518,906 |
| EPS Basic Total Ops | 0.35 | 0.34 | 0.37 | 0.27 | 0.32 |
| EPS Basic Continuous Ops | 0.35 | 0.34 | 0.37 | 0.27 | 0.32 |
| EPS Diluted Total Ops | 0.35 | 0.33 | 0.37 | 0.27 | 0.32 |
| EPS Diluted Continuous Ops | 0.35 | 0.33 | 0.37 | 0.27 | 0.32 |
| EBITDA(a) | $2,366,135 | $2,214,909 | $2,568,208 | $1,962,620 | $2,233,617 |